Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spartalizumab + dabrafenib + trametinib in BRAF V600 mutant melanoma
NCT02967692Phase 3Terminated
- Sponsor
- Novartis
- Start
- Feb 2017
- Primary completion
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial of spartalizumab in melanoma (4 arms), sponsored by Novartis. Primary endpoints: Dose Limiting Toxicities at 8 weeks, Change From Baseline in Programmed Cell Death-ligand 1 Expression at 57 days and 2 more. Started Feb 2017; status: terminated.
02
Drugs
spartalizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02967692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02967692.